Monopar: A Rare Disease Asset With Heavy-Metal Upside (Initiating Buy)

Buy Monopar Therapeutics (MNPR) stock: ALXN1840 Phase 3 Wilson disease data supports a $145 target, $750M peak sales & 2027 runway. See more here.

Summary - I initiate coverage of Monopar Therapeutics with a BUY rating, targeting $145 per share based on ALXN1840's probability-adjusted commercial potential. - ALXN1840 demonstrated significant neurological benefit and copper mobilization in Wilson disease, with an impressive NNT of six and strong Phase 3 data. - My valuation assumes $750M in global peak sales, an 80% probability of success, and a robust cash runway through 2027, supporting regulatory and commercial milestones.

- Key risks include FDA regulatory uncertainty, commercial adoption challenges, and Monopar's lack of prior commercial execution, but current valuation underappreciates upside. Analyst’s Disclosure: I/we have a beneficial long position in the shares of MNPR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions.

I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I do not provide personal investment advice.

All content in this article, including but not limited to opinions, analyses, commentaries, forecasts, stock picks, and investment strategies, is for informational and educational purposes only and should not be interpreted as financial or investment advice. While I strive to provide accurate and up-to-date information, the content may contain errors, inaccuracies, or omissions. Any financial decisions or investments made based on the information presented in this article are solely at your own risk.

I am not responsible for any financial losses, damages, or other consequences resulting from actions taken in reliance on the information provided. You should conduct your own due diligence and consult with a qualified financial professional before making any investment decisions. This article reflects my personal views and opinions and is not affiliated with any employer, financial institution, or advisory firm.

No representations or warranties are made regarding the completeness, accuracy, or reliability of the content, including any external links provided. Any third-party links are for informational purposes only, and I do not endorse or take responsibility for the content or services offered by external sources. All information is provided on an "as is" basis without any express or implied warranties.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole.

Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party